1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s1353-8020(08)70017-8" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s1353-8020(08)70017-8</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
S281-S291
Volume
13
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
Publisher
An entity responsible for making the resource available
Parkinsonism & Related Disorders
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007
Subject
The topic of the resource
A(2A) receptor antagonists; adenosine; alzheimers-disease; amyloid precursor protein; antagonist; bcl-2 family-members; designed multiple ligands; double-blind; dual mechanism; iron chelation; ladostigil; M30; mao-b; monoamine-oxidase-b; neurodegenerative diseases; Neurosciences & Neurology; nmda receptor; rasagiline; tea polyphenol (-)-epigallocatechin-3-gallate
Creator
An entity primarily responsible for making the resource
Youdim M B H; Geldenhuys W J; Van der Schyf C J
Description
An account of the resource
Parkinson's disease (PD) is a severe neurodegenerative disorder, with no available drugs able to prevent the neuronal cell loss characteristic in brains of patients suffering from PD. Due to the complex cascade of molecular events involved in the etiology of PD, an innovative approach towards neuroprotection or neurorescue may entail the use of multifunctional pharmaceuticals that target an array of pathological pathways, each of which is believed to contribute to events that ultimately lead to neuronal cell death. Here we discuss examples of novel multifunctional ligands that may have potential as neuroprotective and neurorestorative therapeutics in PD. The compounds discussed originate from synthetic chemistry as well as from natural sources where various moieties, identified in research to possess neuroprotective and neurorestorative properties, have been introduced into the structures of several monomodal drugs, some of which are used in the clinic. (C) 2007 Elsevier B.V. All rights reserved.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s1353-8020(08)70017-8" target="_blank" rel="noreferrer noopener">10.1016/s1353-8020(08)70017-8</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2007
A(2A) receptor antagonists
adenosine
alzheimers-disease
amyloid precursor protein
Antagonist
bcl-2 family-members
designed multiple ligands
double-blind
dual mechanism
Geldenhuys W J
iron chelation
Journal Article
ladostigil
M30
mao-b
monoamine-oxidase-b
Neurodegenerative Diseases
Neurosciences & Neurology
nmda receptor
Parkinsonism & Related Disorders
rasagiline
tea polyphenol (-)-epigallocatechin-3-gallate
Van der Schyf C J
Youdim M B H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/b978-0-12-386467-3.00006-6" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/b978-0-12-386467-3.00006-6</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
107-125
Volume
100
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
MULTIMODAL DRUGS AND THEIR FUTURE FOR ALZHEIMER'S AND PARKINSON'S DISEASE
Publisher
An entity responsible for making the resource available
Monoamine Oxidases and Their Inhibitors
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011
Subject
The topic of the resource
designed multiple ligands; gamma agonist; inflammatory response; ischemia-reperfusion injury; mitochondrial-membrane protein; monoamine-oxidase-b; multifunctional drugs; neurodegenerative disorders; pioglitazone; ppar-gamma; receptor antagonist
Creator
An entity primarily responsible for making the resource
Van der Schyf C J; Geldenhuys W J
Description
An account of the resource
This chapter discusses the rationale for developing multimodal or multifunctional drugs (also called designed multiple ligands or DMLs) aimed at disease-modifying treatment strategies for the most common neurodegenerative diseases Alzheimer's and Parkinson's disease (AD and PD). Both the prevalence and incidence of AD and PD have seen consistent and dramatic increases, a disconcerting phenomenon which, ironically, has been attributed to extended life expectancy brought about by better health care globally. In spite of these statistics, the development and introduction to the clinic of new therapies proven to prevent or delay the onset of AD and PD have been disappointing. Evidence has accumulated to suggest that the etiopathology of these diseases is extremely complex, with an array of potential drug targets located within a number of deleterious biochemical pathways. Therefore, in these diseases, it is unlikely that the complex pathoetiological cascade leading to disease initiation or progression will be mitigated by any one drug acting on a single pathway or target. The pursuit of novel DMLs may offer far better outcomes. Although certainly not the only, and perhaps not even the best, approach but farthest along the drug development pipeline in the DML paradigm are drugs that combine inhibition of monoamine oxidase with associated etiological targets unique to either AD or PD. These compounds will constitute the major focus of this chapter, which will also explore radically new paradigms that seek to combine cognitive enhancers with proneurogenesis compounds.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/b978-0-12-386467-3.00006-6" target="_blank" rel="noreferrer noopener">10.1016/b978-0-12-386467-3.00006-6</a>
Format
The file format, physical medium, or dimensions of the resource
Book Section
2011
Book Section
designed multiple ligands
gamma agonist
Geldenhuys W J
inflammatory response
ischemia-reperfusion injury
mitochondrial-membrane protein
Monoamine Oxidases and Their Inhibitors
monoamine-oxidase-b
Multifunctional drugs
neurodegenerative disorders
pioglitazone
PPAR-gamma
receptor antagonist
Van der Schyf C J
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1111/j.1471-4159.2006.04141.x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1111/j.1471-4159.2006.04141.x</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
1033-1048
Issue
4
Volume
99
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Multifunctional drugs with different CNS targets for neuropsychiatric disorders
Publisher
An entity responsible for making the resource available
Journal of Neurochemistry
Date
A point or period of time associated with an event in the lifecycle of the resource
2006
2006-11
Subject
The topic of the resource
alzheimers-disease; alzheimers-disease; amyotrophic lateral sclerosis; Biochemistry & Molecular Biology; depressive illness; designed multiple ligands; hetero-cage compounds; iron chelator; Lewy body disease; monoamine oxidase inhibitor; mptp-induced neurotoxicity; neurodegenerative diseases; Neurosciences & Neurology; nicotinic acetylcholine-receptors; nonsteroidal antiinflammatory drugs; parkinsons-disease; parkinsons-disease; schizophrenia
Creator
An entity primarily responsible for making the resource
Van der Schyf C J; Geldenhuys W J; Youdim M B H
Description
An account of the resource
The multiple disease etiologies that lead to neuropsychiatric disorders, such as Parkinson's and Alzheimer's disease, amyotrophic lateral sclerosis, Huntington disease, schizophrenia, depressive illness and stroke, offer significant challenges to drug discovery efforts aimed at preventing or even reversing the progression of these disorders. Transcriptomic tools and proteomic profiling have clearly indicated that such diseases are multifactorial in origin. Further, they are thought to be initiated by a cascade of molecular events that involve several neurotransmitter systems. In response to this complexity, a new paradigm has recently emerged that challenges the widely held assumption that 'silver bullet' agents are superior to 'dirty drugs' in therapeutic approaches aimed at the prevention or treatment of neuropsychiatric diseases. A similar pattern of drug development has occurred in strategies for the treatment of cancer, AIDS and cardiovascular diseases. In this review, we offer an overview of therapeutic strategies and novel investigative drugs discovered or developed in our own and other laboratories, that address multiple CNS etiological targets associated with an array of neuropsychiatric disorders.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1111/j.1471-4159.2006.04141.x" target="_blank" rel="noreferrer noopener">10.1111/j.1471-4159.2006.04141.x</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2006
alzheimers-disease
amyotrophic lateral sclerosis
Biochemistry & Molecular Biology
depressive illness
designed multiple ligands
Geldenhuys W J
hetero-cage compounds
iron chelator
Journal Article
Journal of neurochemistry
Lewy body disease
monoamine oxidase inhibitor
mptp-induced neurotoxicity
Neurodegenerative Diseases
Neurosciences & Neurology
nicotinic acetylcholine-receptors
nonsteroidal antiinflammatory drugs
parkinsons-disease
Schizophrenia
Van der Schyf C J
Youdim M B H